News
A prognostic Alzheimer's blood test in the symptom-free state
Forgetfulness is a normal side effect of aging. At what point does this process become pathological? ...
more
Development of Alzheimer's plaques elucidated with infrared microscopy
You can't just look inside a person's head. This makes it difficult to understand what happens in the brain of dementia patients. A new method provides insights. ...
more
Artificial intelligence classifies colorectal cancer using IR imaging
Within just 30 minutes, infrared microscopy can automatically identify the type of colorectal tumor. On this basis, treatment decisions can be made more reliably. ...
more
Challenges of an ageing society
It is not only in Germany that constantly improving living and health conditions are leading to a continuous increase in average life expectancy. Already today, the average life expectancy of newborn women is just under 95 years. The average life expectancy of newborn men is a good 88 years.
However, with increasing life expectancy, classic diseases of the elderly such as cancer and neurological diseases continue to increase. This poses major social and economic challenges not only for those affected and their relatives, but also for our healthcare system.
Our mission
Method development for (early) diagnostics and therapy prediction
In order to meet the challenges of an ageing society, the primary goal at the Centre for Protein Diagnostics (PRODI) is the development of new, minimally invasive methods for diagnostics and therapy prediction. The focus is on neurological and oncological diseases. In particular, innovative methods are being developed that provide precise information about diseases and individual therapy responses already at early stages of the disease.
Goals of PRODI
1. further development and application of marker-free vibration spectroscopic, proteome-analytical and bioinformatics methods in basic protein research and in application-oriented diagnostics and therapy prediction of neurological and oncological diseases
2. translation of the methods into the clinic
3. support of start-ups in the “seed” phase
Our vision
When proteins make you sick
Practically all oncological and neurodegenerative diseases are associated with protein changes. Proteins regulate all life processes in nature and determine, among other things, the growth and division of cells. Even changes in a single protein can trigger serious oncological and neurodegenerative diseases. Often, macroscopically visible, morphological changes in tissue do not occur until many years after the protein changes have occurred. Therefore, at the Centre for Protein Diagnostics we analyse macroscopic changes in tissue, changes in cells as well as protein changes on the molecular level across scales. The investigations of proteins at the molecular level complement the work at the Chair of Biophysics at the Ruhr University Bochum.
Detecting diseases earlier
The protein changes mentioned can serve as biomarkers to detect diseases phenotypically in early, still symptomless disease stages (principle of secondary prevention). If certain proteins are identified as “key players”, it is possible to intervene specifically in the causative factors as well as in the disease process itself – in the sense of early therapy. Once these protein biomarkers have been validated, they can also be used to monitor the course of therapy and even predict the success of therapy. This enables individual, precise medicine with new therapeutic approaches.
A small prick for prevention
One blood sample, one urine sample, and all important preventive examinations are done – that is the vision that drives the researchers in PRODI. They rely on criminalistic methods: just as every person has a unique fingerprint, there is a characteristic protein profile for every disease. Certain proteins that also occur in the healthy body are massively overproduced or altered by diseased cells. If these proteins and their profile are known, they can be specifically searched for, for example in the blood or urine. If diseases such as cancer or Alzheimer’s disease are detected at an early, but still asymptomatic stage, they can be treated much more gently and successfully.
Our areas of expertise
In order to achieve the above-mentioned goals, we have established a highly efficient workflow in PRODI, which ranges from sample collection and characterisation in the Experimental Medicine competence area and in cooperating clinics, to detailed coordinated analyses in the Biospectroscopy and Medical Proteome Analysis competence areas, to cross-platform evaluation of the acquired data in the Bioinformatics competence area.
Biospectroscopy
In the competence area of Biospectroscopy, non-invasive, marker-free vibration spectroscopic (imaging) methods are used and further developed for the characterisation of tissue, cells and body fluids.
Experimental medicine
Experimental medicine brings together experimental clinical expertise in the field of pathological, oncological and neurological research.
Medical proteome analysis
In the competence area of Medical Proteome Analysis, mass spectrometry-based and proteomics technologies are used and further developed for the characterisation of tissues, cells and body fluids.
Bioinformatics
In the bioinformatics competence area, cross-platform data analysis and the development of new bioinformatics approaches take place. It bridges the gap between genome, transcriptome and proteome.